3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
A critical appraisal of the HORIZON-PFT trial examining enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest disclosures, and what post-publication commentary revealed about yearly IV zoledronic acid for osteoporosis.
Deep dive into the HORIZON-PFT extension study: how zoledronic acid's fracture protection held up beyond 3 years, what safety signals emerged, and clinical implications for long-term bisphosphonate therapy.
Complete breakdown of HORIZON-PFT trial outcomes for zoledronic acid IV: primary and secondary endpoint effect sizes, confidence intervals, time-course data, and subgroup analyses from the landmark 2007 NEJM publication.